PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19628124-8	2009	There was a 40% reduction in major bleeding with fondaparinux compared with enoxaparin in those treated with GP IIb/IIIa (5.2% vs. 8.3%, hazard ratio [HR]: 0.61, p < 0.001).	Enoxaparin	76-86	integrin subunit alpha 2b	Homo sapiens	109-115	
12730628-9	2003	Our small observational study shows that IV enoxaparin is safe and efficacious during PCI when given at a dose 33% lower than previously reported in conjunction with any GP IIb/IIIa inhibitor and Angio-Seal.	Enoxaparin	44-54	integrin subunit alpha 2b	Homo sapiens	170-176	
12730628-10	2003	However, large, randomized PCI trials are needed to confirm the clinical efficacy, safety and cost-effectiveness of lower doses of enoxaparin with GPIIb/IIIa inhibitors and vascular closure devices.	Enoxaparin	131-141	integrin subunit alpha 2b	Homo sapiens	147-152	
11019977-7	2000	At high pharmacologic concentrations, unfractionated heparin and enoxaparin, but not hirudin, further reduced factor V/Va binding to the surface of activated platelets in the presence of GPIIb-IIa antagonists.	Enoxaparin	65-75	integrin subunit alpha 2b	Homo sapiens	187-192